Acyclovir Dosing for Chickenpox
For chickenpox treatment, use oral acyclovir 20 mg/kg per dose (maximum 800 mg/dose) four times daily for 5 days in children, and 800 mg four times daily for 5 days in adults and children over 40 kg. 1
Dosing by Patient Population
Children (2 years and older)
- 20 mg/kg per dose orally 4 times daily for 5 days (total daily dose: 80 mg/kg/day)
- Maximum single dose: 800 mg
- Children over 40 kg should receive the adult dose 1
Adults and Adolescents (>40 kg)
- 800 mg orally 4 times daily for 5 days 1
Immunocompromised Patients
For HIV-infected or severely immunosuppressed patients with chickenpox:
- Oral: 20 mg/kg (max 800 mg/dose) 4 times daily for 7-10 days or until no new lesions for 48 hours 2
- IV route: Consider for severe immune suppression at 10 mg/kg IV every 8 hours (or 500 mg/m² IV every 8 hours as alternative dosing) 2
Critical Timing Considerations
Initiate therapy within 24 hours of rash onset for maximum benefit. The evidence strongly demonstrates a gradation in clinical response correlating with timing:
- First 24 hours: Greatest reduction in lesion count, faster healing, shorter fever duration, and reduced viral shedding 3, 4, 5
- 24-48 hours: Some benefit remains, particularly in adolescents and children, but effects are diminished 3
- After 48 hours: Efficacy is substantially reduced 3, 6
Treatment initiated on day 1 of rash showed significantly faster time to maximum lesion formation and 50% healing compared to day 2 or 3 initiation 3.
Duration of Therapy
Five days of treatment is sufficient—a controlled trial demonstrated that 7 days provided no additional clinical benefit over 5 days 3. The FDA-approved duration is 5 days for immunocompetent patients 1.
Renal Dose Adjustments
Modify dosing based on creatinine clearance 1:
- CrCl >10 mL/min: 800 mg every 4 hours (5 times daily)
- CrCl 10-25 mL/min: 800 mg every 8 hours
- CrCl 0-10 mL/min: 800 mg every 12 hours
- Hemodialysis: Administer additional dose after each dialysis session
Clinical Efficacy Evidence
Multiple randomized controlled trials demonstrate that acyclovir:
- Reduces mean lesion count (294 vs 347 with placebo) 4
- Decreases proportion with >500 lesions (21% vs 38%) 4
- Stops new lesion formation by day 3 in >95% of patients 4
- Shortens fever duration to 3-4 days (vs >4 days in 20% of placebo recipients) 4
- Accelerates progression to crusted/healed stages 4, 5
The treatment is well-tolerated with no significant increase in adverse events compared to placebo 4, 5.
Important Caveats
Viral resistance: A controlled trial found no emergence of acyclovir-resistant virus during treatment, with viruses maintaining normal thymidine kinase function 3. However, the effect on latent virus was not assessed.
Antibody response: Acyclovir recipients may have lower antibody titers at 4 weeks post-illness, but titers equalize by 1 year 5. This does not appear clinically significant.
Complications: While acyclovir reduces symptom duration and severity, studies have not definitively shown reduction in rare serious complications like bacterial superinfection or cerebellar ataxia 4. The incidence of complications remained similar between treatment groups (10-13.5%) 5.
Intravenous acyclovir is indicated for immunocompromised patients or those with severe disease complications like pneumonitis 1, 7. Adequate hydration must be maintained, and mental status should be monitored at these higher doses 7.